The importance of intellectual property rights in biotechnology cannot be underestimated

Biotech innovation is an extremely complex process. Especially the early stages carry a significant level of financial risk and later on regulatory hurdles make the way to gain commercial success difficult.

Securing patent rights as well as optimising the financial benefits from your innovation through the correct deployment of patent rights are therefore essential.

These are issues which our European Patent Attorneys (EPAs) fully understand. Our EPAs have decades of experience developing and implementing tailored IP strategies to help ambitious and innovative companies of all sizes achieve commercial success.

Highly qualified scientific thinking, commercial mindset and specialised legal expertise help us create strategies that support your commercial objectives.

We have an outstanding history of providing strategic advice, from the first invention disclosure to assisting with developing a business plan, and through to ensuring your IP portfolios are structured with your commercial goals in mind. These goals can be to attract private or venture capital funding, secure licensing deals, or exit via a sale.

Our track record also includes supporting clients preparing for IPO, and we have advised on a number of successful trade sales.

As with all our key industry sectors, aera offers a full range of drafting and prosecution services for patents together with oppositions and appeal procedures.

The strong technical expertise of our biotech team covers all aspects, including:

  • Industrial biotechnology
  • Clinical medicine
  • Diagnostics
  • Immunology
  • Stem cell research
  • Microbiology
  • Protein technology
  • Molecular biology
  • Genetics
  • Vaccine Technology
  • Virology

aera has many direct clients. This inevitably means that we manage and coordinate the prosecution of patent applications all over the world – with the support of our large network of overseas attorneys.

We also prosecute a large number of cases from foreign associates and help securing and defending Scandinavian and European patent rights for international life-science companies, universities, and even governments.



The Legal Board of Appeal (LBoA) of the European Patent Office (EPO) concluded in the recent decision J5/23 that „signature“ within Article 72 of the European Patent Convention (EPC) demands distinct and handwritten names on the assignment contract, rendering a text string signature insufficient and the assignment invalid. The decision […]

30. October 2023
Read more


Videos and presentations Richard Hung (MORRISON & FOERSTER): Why bother with IP litigation in the US? US IP litigation is from a European perspective perceived as costly, not worth it. It is complicated and longsome and you rarely hear people in the states say that they love IP litigation. But […]

17. May 2022
Read more


Willem Hoyng: The wolf IS coming – future IP litigation under the UPC What will change strategically when the UPC enters into force in the fall? Will Scandinavian industry now be haunted by obscure patentees, will we see trolls gearing up in Europe, or will everybody opt out? How do […]

9. May 2022
Read more